CTOs on the Move

Avadim Health

www.avadimhealth.com

 
Avadim Health is a life sciences company that offers advanced, safe solutions in everything from immune health to neuromuscular care. They are committed to helping those in need benefit from their products and have a strong pipeline across a broad rang...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Bloodworth Wholesale

Bloodworth Wholesale is a Tifton, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astellas Pharma

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.

Pharmacyvillage.com

Pharmacyvillage.com is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rising Pharmaceuticals

Rising Pharmaceuticals is an industry leader in marketing and distributing innovative branded and multi-source prescription and over-the-counter pharmaceutical products.

Tricida

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.